Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Leukemia, Myeloid, Chronic-Phase
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles

abstract

  • Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity. Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.14.9260

PubMed ID

  • 18541900

Additional Document Info

start page

  • 3204

end page

  • 12

volume

  • 26

number

  • 19